MDL 28133A

Drug Profile

MDL 28133A

Latest Information Update: 06 Nov 1997

Price : $50

At a glance

  • Originator Aventis
  • Class Antiplatelets
  • Mechanism of Action Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Coronary thrombosis; Thrombosis

Most Recent Events

  • 06 Nov 1997 No-Development-Reported for Coronary thrombosis in USA (Unknown route)
  • 06 Nov 1997 No-Development-Reported for Thrombosis in USA (Unknown route)
  • 15 Dec 1994 A study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top